Covis Pharma gains rights to certain GSK drugs in US and Puerto Rico
Covis aims to build sales in new and adjacent therapeutic areas
Swiss specialist pharmaceutical firm Covis Pharma has acquired full commercial rights to GlaxoSmithKline’s Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate), and Zantac Injection (ranitidine hydrochloride) in the US and Puerto Rico.
GSK will retain the existing rights for these products in countries outside the US. Terms of the agreement have not been disclosed.
‘We are very pleased to announce the acquisition of this portfolio of drugs as we establish Covis as a leading specialist pharmaceutical company,’ said Jack Davis, chief executive of Covis Pharma, which is headquartered in Zug.
‘Our management team looks forward to building out our platform beyond the current focus on the acute care, cardiovascular and CNS markets, into new and adjacent therapeutic areas.’
Covis Pharmaceuticals Inc (USA), a Raleigh, North Carolina-based affiliate will provide US sales and distribution support to Covis Pharma.
GSK will manufacture and supply Fortaz Injection, Zinacef Injection, Parnate, and Zantac Injection to Covis. Lanoxin Tablets and Injection, Fortaz Frozen, Zinacef Frozen and Zantac Injection Premixed will continue to be manufactured and supplied by current third-party suppliers.